US Patent

US11911386 — Methods of treating B-cell proliferative disorder

Method of Use · Assigned to BeiGene Switzerland GmbH · Expires 2043-01-19 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating a patient with a B-cell proliferative disorder by administering zanubrutinib, with a moderate CYP3A inducer.

USPTO Abstract

Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3715 — Brukinsa
U-3715 — Brukinsa

Patent Metadata

Patent number
US11911386
Jurisdiction
US
Classification
Method of Use
Expires
2043-01-19
Drug substance claim
No
Drug product claim
No
Assignee
BeiGene Switzerland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.